EQRX
Price:
$2.34
Market Cap:
$1.14B
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical tri...[Read more]
Industry
Biotechnology
IPO Date
2021-06-03
Stock Exchange
NASDAQ
Ticker
EQRX
According to EQRx, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.25. This represents a change of 117.41% compared to the average of -1.96 of the last 4 quarters.
The mean historical PE Ratio of EQRx, Inc. over the last ten years is -8.23. The current -4.25 PE Ratio has changed 5.07% with respect to the historical average. Over the past ten years (40 quarters), EQRX's PE Ratio was at its highest in in the December 2021 quarter at 653.82. The PE Ratio was at its lowest in in the September 2021 quarter at -30.32.
Average
-8.23
Median
-7.12
Minimum
-24.37
Maximum
5.68
Discovering the peaks and valleys of EQRx, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 646.10%
Maximum Annual PE Ratio = 5.68
Minimum Annual Increase = -123.30%
Minimum Annual PE Ratio = -24.37
Year | PE Ratio | Change |
---|---|---|
2022 | 5.68 | -123.30% |
2021 | -24.37 | 93.91% |
2020 | -12.57 | 646.10% |
The current PE Ratio of EQRx, Inc. (EQRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-10.42
5-year avg
-8.23
10-year avg
-8.23
EQRx, Inc.’s PE Ratio is less than Century Therapeutics, Inc. (-0.91), greater than Edgewise Therapeutics, Inc. (-14.14), less than C4 Therapeutics, Inc. (-3.44), greater than Mineralys Therapeutics, Inc. (-4.63), greater than Cullinan Oncology, Inc. (-6.96), less than Lyell Immunopharma, Inc. (-1.42), less than Monte Rosa Therapeutics, Inc. (-3.11), less than Theseus Pharmaceuticals, Inc. (-3.19), greater than Revolution Medicines, Inc. (-13.31), less than Relay Therapeutics, Inc. (-2.57), greater than Stoke Therapeutics, Inc. (-7.92), less than Pliant Therapeutics, Inc. (-4.19), less than Black Diamond Therapeutics, Inc. (-3.70), greater than Arvinas, Inc. (-5.42), greater than Blueprint Medicines Corporation (-26.44), greater than Sana Biotechnology, Inc. (-4.82), greater than Kymera Therapeutics, Inc. (-21.01), less than Erasca, Inc. (-3.94), less than NGM Biopharmaceuticals, Inc. (-0.91), greater than Keros Therapeutics, Inc. (-11.28),
Company | PE Ratio | Market cap |
---|---|---|
-0.91 | $123.69M | |
-14.14 | $1.64B | |
-3.44 | $374.42M | |
-4.63 | $558.43M | |
-6.96 | $1.04B | |
-1.42 | $299.52M | |
-3.11 | $349.21M | |
-3.19 | $181.50M | |
-13.31 | $6.99B | |
-2.57 | $835.47M | |
-7.92 | $773.92M | |
-4.19 | $782.51M | |
-3.70 | $305.13M | |
-5.42 | $1.68B | |
-26.44 | $5.47B | |
-4.82 | $1.12B | |
-21.01 | $2.89B | |
-3.94 | $807.96M | |
-0.91 | $128.53M | |
-11.28 | $1.97B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like EQRx, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like EQRx, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is EQRx, Inc.'s PE Ratio?
How is the PE Ratio calculated for EQRx, Inc. (EQRX)?
What is the highest PE Ratio for EQRx, Inc. (EQRX)?
What is the 3-year average PE Ratio for EQRx, Inc. (EQRX)?
What is the 5-year average PE Ratio for EQRx, Inc. (EQRX)?
How does the current PE Ratio for EQRx, Inc. (EQRX) compare to its historical average?